GCEA Value Flower: Summary and A Path Forward

Meng Li (2024) has a nice summary of the generalized cost effectiveness analysis (GCEA) user guide paper (see Shafrin et al. 2024) that was published last month. The GCEA methodology encompasses 15 ‘petals’ across four domains. The uncertainty domain captures how risk aversion and uncertainty in treatment outcomes impact value, including aspects such as outcome…

Read More

Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease

The FDA cited deficiencies in its govorestat’s application in galactosemia, a rare metabolic disease, Applied Therapeutics said. The biotech is still on track to submit a separate application for the drug in sorbitol dehydrogenase (SORD) deficiency, another rare disease that has no FDA-approved therapies. The post Applied Therapeutics Drug Is Denied FDA Approval in Rare…

Read More

Medicaid Postpartum Coverage Extension Tracker

This page tracks recent state actions to extend Medicaid postpartum coverage, including approved and pending 1115 waivers, legislation that will require the state to seek federal approval through a SPA or 1115 waiver, submitted and approved SPAs, and coverage financed solely with state funds.

Read More

5 strategies on how to increase outpatient revenue

The growing shift from inpatient to outpatient care continues. The U.S. ambulatory services market was estimated at USD 289.5 billion in 2023and is projected to grow at a CAGR of 5.38% from 2024 to 2030. ADeloitte study notes that the gap between inpatient and outpatient revenue has been closing for two decades. But what’s driving…

Read More